194 related articles for article (PubMed ID: 9408695)
1. Oral ganciclovir in pediatric transplant recipients: a pharmacokinetic study.
Pescovitz MD; Brook B; Jindal RM; Leapman SB; Milgrom ML; Filo RS
Clin Transplant; 1997 Dec; 11(6):613-7. PubMed ID: 9408695
[TBL] [Abstract][Full Text] [Related]
2. A randomized prospective controlled trial of oral ganciclovir versus oral valacyclovir for prophylaxis of cytomegalovirus disease after renal transplantation.
Reischig T; Opatrny K; Bouda M; Treska V; Jindra P; Svecova M
Transpl Int; 2002 Dec; 15(12):615-22. PubMed ID: 12478408
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of oral ganciclovir in prevention of cytomegalovirus infection in post-kidney transplant patients.
Ahsan N; Holman MJ; Yang HC
Clin Transplant; 1997 Dec; 11(6):633-9. PubMed ID: 9408699
[TBL] [Abstract][Full Text] [Related]
4. Randomized controlled trial of oral ganciclovir versus oral acyclovir after induction with intravenous ganciclovir for long-term prophylaxis of cytomegalovirus disease in cytomegalovirus-seropositive liver transplant recipients.
Winston DJ; Busuttil RW
Transplantation; 2003 Jan; 75(2):229-33. PubMed ID: 12548129
[TBL] [Abstract][Full Text] [Related]
5. Delay of CMV infection in high-risk CMV mismatch lung transplant recipients due to prophylaxis with oral ganciclovir.
Palmer SM; Grinnan DC; Diane Reams B; Steele MP; Messier RH; Duane Davis R
Clin Transplant; 2004 Apr; 18(2):179-85. PubMed ID: 15016133
[TBL] [Abstract][Full Text] [Related]
6. Late cytomegalovirus infection after oral ganciclovir prophylaxis in renal transplant recipients.
Murray BM; Subramaniam S
Transpl Infect Dis; 2004 Mar; 6(1):3-9. PubMed ID: 15225220
[TBL] [Abstract][Full Text] [Related]
7. Prevention of primary cytomegalovirus disease in organ transplant recipients with oral ganciclovir or oral acyclovir prophylaxis.
Rubin RH; Kemmerly SA; Conti D; Doran M; Murray BM; Neylan JF; Pappas C; Pitts D; Avery R; Pavlakis M; Del Busto R; DeNofrio D; Blumberg EA; Schoenfeld DA; Donohue T; Fisher SA; Fishman JA
Transpl Infect Dis; 2000 Sep; 2(3):112-7. PubMed ID: 11429021
[TBL] [Abstract][Full Text] [Related]
8. A comparative randomised study of valacyclovir vs. oral ganciclovir for cytomegalovirus prophylaxis in renal transplant recipients.
Pavlopoulou ID; Syriopoulou VP; Chelioti H; Daikos GL; Stamatiades D; Kostakis A; Boletis JN
Clin Microbiol Infect; 2005 Sep; 11(9):736-43. PubMed ID: 16104989
[TBL] [Abstract][Full Text] [Related]
9. Allograft rejection predicts the occurrence of late-onset cytomegalovirus (CMV) disease among CMV-mismatched solid organ transplant patients receiving prophylaxis with oral ganciclovir.
Razonable RR; Rivero A; Rodriguez A; Wilson J; Daniels J; Jenkins G; Larson T; Hellinger WC; Spivey JR; Paya CV
J Infect Dis; 2001 Dec; 184(11):1461-4. PubMed ID: 11709790
[TBL] [Abstract][Full Text] [Related]
10. [Effectiveness of preemptive therapy with ganciclovir in recipients of renal transplants at high risk (R-/D+) for the development of cytomegalovirus disease].
Aranda-Verástegui F; Alberú J; Soto-Ramírez LE; González-Aguirre H; Muñoz Trejo T; Mancilla E; Díliz H; Correa-Rotter R; Sierra-Madero J
Rev Invest Clin; 2002; 54(3):198-203. PubMed ID: 12183888
[TBL] [Abstract][Full Text] [Related]
11. Randomized controlled trial of sequential intravenous and oral ganciclovir versus prolonged intravenous ganciclovir for long-term prophylaxis of cytomegalovirus disease in high-risk cytomegalovirus-seronegative liver transplant recipients with cytomegalovirus-seropositive donors.
Winston DJ; Busuttil RW
Transplantation; 2004 Jan; 77(2):305-8. PubMed ID: 14742998
[TBL] [Abstract][Full Text] [Related]
12. A pilot phase II study of alternate day ganciclovir and foscarnet in preventing cytomegalovirus (CMV) infections in at-risk pediatric and adolescent allogeneic stem cell transplant recipients.
Shereck EB; Cooney E; van de Ven C; Della-Lotta P; Cairo MS
Pediatr Blood Cancer; 2007 Sep; 49(3):306-12. PubMed ID: 16972242
[TBL] [Abstract][Full Text] [Related]
13. [Prevention of cytomegalovirus infection following heart transplantation].
Laske A; Carrel T; Niederhäuser U; Bauer E; Pasic M; von Segesser LK; Gallino A; Turina M
Helv Chir Acta; 1992 Jan; 58(4):527-32. PubMed ID: 1316336
[TBL] [Abstract][Full Text] [Related]
14. Cytomegalovirus prophylaxis with ganciclovir in kidney transplant recipients receiving induction antilymphocyte antibodies.
Said T; Nampoory MR; Johny KV; Pacsa AS; Mini Abraham P; Nair MP; Abdel-Haleem M; Samhan M; Al-Mousawi M
Transplant Proc; 2004; 36(6):1847-9. PubMed ID: 15350495
[TBL] [Abstract][Full Text] [Related]
15. 24-week oral ganciclovir prophylaxis in kidney recipients is associated with reduced symptomatic cytomegalovirus disease compared to a 12-week course.
Doyle AM; Warburton KM; Goral S; Blumberg E; Grossman RA; Bloom RD
Transplantation; 2006 Apr; 81(8):1106-11. PubMed ID: 16641594
[TBL] [Abstract][Full Text] [Related]
16. Preemptive use of oral ganciclovir to prevent cytomegalovirus infection in liver transplant patients: a randomized, placebo-controlled trial.
Paya CV; Wilson JA; Espy MJ; Sia IG; DeBernardi MJ; Smith TF; Patel R; Jenkins G; Harmsen WS; Vanness DJ; Wiesner RH
J Infect Dis; 2002 Apr; 185(7):854-60. PubMed ID: 11920308
[TBL] [Abstract][Full Text] [Related]
17. Oral ganciclovir dosing in transplant recipients and dialysis patients based on renal function.
Pescovitz MD; Pruett TL; Gonwa T; Brook B; McGory R; Wicker K; Griffy K; Robinson CA; Jung D
Transplantation; 1998 Oct; 66(8):1104-7. PubMed ID: 9808499
[TBL] [Abstract][Full Text] [Related]
18. Prophylactic oral ganciclovir after renal transplantation-dosing and pharmacokinetics.
Filler G; Lampe D; von Bredow MA; Lappenberg-Pelzer M; Rocher S; Strehlau J; Ehrich JH
Pediatr Nephrol; 1998 Jan; 12(1):6-9. PubMed ID: 9502557
[TBL] [Abstract][Full Text] [Related]
19. Oral ganciclovir shows benefit for prevention of CMV disease in liver transplant recipients.
J Int Assoc Physicians AIDS Care; 1996 Jul; 2(7):43-4. PubMed ID: 11363747
[TBL] [Abstract][Full Text] [Related]
20. Valganciclovir Dosing for Cytomegalovirus Prophylaxis in Pediatric Solid-organ Transplant Recipients: A Prospective Pharmacokinetic Study.
Peled O; Berkovitch M; Rom E; Bilavsky E; Bernfeld Y; Dorfman L; Pappo A; Ziv-Baran T; Brandriss N; Bar-Haim A; Amir J; Ashkenazi-Hoffnung L
Pediatr Infect Dis J; 2017 Aug; 36(8):745-750. PubMed ID: 28383392
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]